The Week

SCNI.US fell 6.02% this week to close at $1.56, underperforming the S&P 500 by about 5.94 percentage points (the S&P 500 was -0.08%). The week opened sharply higher and then reversed: on Monday, 14 September, the stock opened at $2.33, touched an intraday high of $2.67 and closed at $2.44; on Tuesday, 15 September, it gapped lower to $1.84, dipped to $1.50 and closed at $1.54; over the next three sessions it traded in a $1.43-$1.77 range before finishing at $1.56. Weekly amplitude reached 53.22%, with total volume of about 43.51m shares. Monday alone accounted for roughly 94% of that volume at 41.06m shares, making it the most concentrated session of the week.

Key Events

The week’s story revolved around extremely volatile, non-fundamental trading in SCNI.US. On Monday, 14 September, Scinai Immunotherapeutics surged about 53% intraday and appeared in multiple health-care stock movers lists. From early Tuesday, after-hours and overnight trading turned sharply lower; pre-market quotes fell more than 21% at one point, and the intraday drop widened to around 31.56% with unusually heavy turnover. On Wednesday, 16 September, overnight coverage mentioned the termination of a consulting agreement, one of the few company-specific clues in the week; the stock fell about 7% pre-market and settled near $1.52. On Thursday, 17 September, it rose 7.89% overnight again without major news. Overall, the week’s swings were driven mainly by capital flows and volatility rather than earnings, product approvals or major partnerships.

Analyst Ratings

One analyst currently rates SCNI.US a buy, with zero holds and zero underperform or sell ratings, for a total of one covering institution. The consensus rating is strong buy, and the consensus target price is $7,000, about 448,617.95% above the current price of $1.56. The highest and lowest target prices are both $7,000, so no dispersion of views is visible from a single house. Within the biotechnology industry, the stock ranks 468th out of 501 names, placing it toward the lower end of the cohort. Note that the consensus rating and target price were last updated on 3 January 2024, so this is a stale aggregate and no rating direction change was provided this week.

The Week Ahead

Next week brings a relatively busy US macro calendar. On Tuesday, 22 September, the Richmond Fed composite index is due, with a prior reading of 4. On Wednesday, 23 September, EIA weekly crude oil inventories and Cushing crude oil inventories will be published. Thursday, 24 September, brings initial jobless claims, the current account balance, new home sales annual rate, and EIA natural gas storage change. For SCNI.US itself, no company-specific earnings or major event has been scheduled, so the focus will be on whether it can hold its current trading range after the sharp swings, and how macro data affects risk appetite across the biotech sector.

In Short

The core tension this week is between the stock’s -6.02% weekly decline and its brief surge toward $2.67 on Monday. On the money-flow side, the latest trading day showed zero large-order net flow, with medium and small orders moving in opposite directions. Valuation remains relatively low at about 0.89x price-to-book and negative earnings per share, but earnings quality offers little support. On the rating side, a single-cover strong buy and a $7,000 target provide upside reference, but the aggregate is dated and the stock’s trading volatility is extreme. Going forward, the key questions are whether turnover keeps escalating, whether the wild swings begin to narrow, and how macro data feeds into biotech risk appetite.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.